Navigation Links
Trubion Announces Presentations at April/May Investor Conferences

SEATTLE, April 24 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN), today announced that executives will present an overview of the company at two upcoming investor conferences in April and May:
-- April 30: Morgan Stanley Global Healthcare Unplugged Conference at The

Ritz-Carlton, 455 Grand Bay Drive in Key Biscayne, FL. Dr. Peter

Thompson, president, CEO and chairman, is scheduled to present at

9:50 a.m. EDT. The presentation will be available via audio Webcast at

-- May 13: Bank of America 2008 Health Care Conference at the Four

Seasons, 3960 Las Vegas Blvd S in Las Vegas, NV. Michelle Burris,

senior vice president and chief financial officer, is scheduled to

present at 1:20 p.m. PDT. The presentation will be available via audio

Webcast at

About Trubion

Trubion is a biopharmaceutical company that is creating a pipeline of novel protein therapeutic product candidates to treat autoimmune and inflammatory diseases and cancer. The company's mission is to develop a variety of first-in-class and best-in-class product candidates, customized for optimal safety, efficacy, and convenience that it believes may offer improved patient experiences. Trubion's current product candidates are novel single-chain protein, or SMIP(TM), therapeutics, and are designed using its custom drug assembly technology. Trubion's product pipeline includes CD20-directed candidates such as TRU-015 and SBI-087 for autoimmune and inflammatory diseases developed under the company's Wyeth collaboration. Trubion's proprietary product candidate, TRU-016, is a novel CD37-targeted therapy for the treatment of B-cell malignancies currently in Phase 1/2 clinical evaluation. In addition to Trubion's current product candidates, the company is also developing additional alliance and proprietary product candidates that build on its product development experience. More information is available in the investors section of Trubion's website:

For more information, contact:

Trubion Pharmaceuticals, Inc.

Jim DeNike

Senior Director, Corporate Communications


Waggener Edstrom Worldwide Healthcare

Amy Petty

Senior Account Executive

617-576-5788 TRBN-G

SOURCE Trubion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Trubion Pharmaceuticals Inc. Reports Fourth-Quarter and Year-Ended 2007 Financial Results and Provides 2008 Financial Outlook
2. Trubion Pharmaceuticals to Present at the Lazard Capital Markets Healthcare Investor Conference
3. Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2007 Financial Results
4. Trubion Pharmaceuticals Announces Upcoming Presentations at American College of Rheumatology Annual Scientific Meeting
5. Trubion Pharmaceuticals to Present at Upcoming Investor Conferences
6. deCODE genetics Announces Webcast of Conference Call to Discuss First Quarter 2008 Financial Results
7. Abbott Announces Labs Are Vital(TM) Facebook Scholarship Contest Winners
8. Environmental Tectonics Corporations BioMedical Division Announces Sale of Two Hyperbaric Chambers
9. Inverness Medical Innovations Announces First Quarter 2008 Results
10. Aida Pharmaceuticals, Inc. Announces Completion of Research Institute Acquisition
11. Sangamo BioSciences Announces First Quarter Conference Call and Webcast
Post Your Comments:
(Date:10/11/2017)... ... October 11, 2017 , ... ComplianceOnline’s Medical Device Summit is back ... 8th June 2018 in San Francisco, CA. The Summit brings together current and former ... CEOs, board directors and government officials from around the world to address key issues ...
(Date:10/11/2017)...  VMS BioMarketing, a leading provider of patient support solutions, ... Educator (CNE) network, which will launch this week. The VMS ... care professionals to enhance the patient care experience by delivering ... health care professionals to help women who have been diagnosed ... ...
(Date:10/11/2017)... ... October 11, 2017 , ... Disappearing forests and increased emissions ... over 5.5 million people each year. Especially those living in larger cities are affected ... based in one of the most pollution-affected countries globally - decided to take action. ...
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... ... Administration (FDA) has granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal ... the treatment of osteosarcoma. SBT-100 is able to cross the cell membrane and ...
Breaking Biology Technology:
(Date:4/5/2017)... April 4, 2017 KEY FINDINGS ... expand at a CAGR of 25.76% during the forecast ... the primary factor for the growth of the stem ... MARKET INSIGHTS The global stem cell ... application, and geography. The stem cell market of the ...
(Date:3/30/2017)... -- The research team of The Hong Kong Polytechnic ... by adopting ground breaking 3D fingerprint minutiae recovery and matching technology, ... accuracy for use in identification, crime investigation, immigration control, security of ... ... A research team led by Dr ...
(Date:3/27/2017)... March 27, 2017  Catholic Health Services (CHS) ... Systems Society (HIMSS) Analytics for achieving Stage 6 ... sm . In addition, CHS previously earned a ... using an electronic medical record (EMR). ... level of EMR usage in an outpatient setting.  ...
Breaking Biology News(10 mins):